A Phase 1 Open-Label Study to Assess the Pharmacokinetics, Safety, and Tolerability of Intravenous Administration of Plazomicin in Subjects With End Stage Renal Disease (ESRD) Receiving Intermittent Hemodialysis (IHD)
Latest Information Update: 03 Aug 2021
At a glance
- Drugs Plazomicin (Primary)
- Indications Bacteraemia; Nosocomial pneumonia; Pyelonephritis; Urinary tract infections
- Focus Pharmacokinetics
- Sponsors Cipla USA
- 27 Jul 2021 Status changed from active, no longer recruiting to completed.
- 01 May 2021 Planned End Date changed from 1 Apr 2021 to 1 Jun 2021.
- 01 May 2021 Status changed from recruiting to active, no longer recruiting.